Granted Patent
B2
US 12,427,200 · App. 17/887,776 · Granted Sep 30, 2025
Compositions and methods for the treatment of viral infections
Inventors:
Allen Borchardt (San Diego, CA); Thomas P. Brady (San Diego, CA); Zhi-Yong Chen (La Jolla, CA); Thanh Lam (San Diego, CA); Leslie W. Tari (San Diego, CA)
Assignee:
Cidara Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).
Claims (41)
1. A method of treating a subject having an influenza infection, the method comprising administering to the subject a conjugate described by formula (D-II-6):
wherein each E comprises an Fc domain monomer;
n is 1 or 2;
T is an integer from 1 to 20;
L is a linker;
R 7 is selected from C 1 -C 20 alkyl; and
the squiggly line indicates that L is covalently attached to E;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the squiggly line indicates that L is covalently attached to a nitrogen atom of a solvent-exposed lysine of E.
3. The method of claim 1 , wherein the squiggly line indicates that L is covalently attached to a sulfur atom of a solvent-exposed cysteine of E.
4. The method of claim 1 , wherein n is 2, and the two Es dimerize with each other to form an Fc domain.
5. The method of claim 1 , wherein T is an integer from 1 to 10.
6. The method of claim 1 , wherein R 7 is methyl, ethyl, propyl, or butyl.
7. The method of claim 6 , wherein the conjugate is described by formula (D-II-7):
or a pharmaceutically acceptable salt thereof.
8. The method of claim 7 , wherein the conjugate is described by formula (D-II-8):
wherein L′ is the remainder of L, and
y 1 and y 2 are each independently an integer from 1-20,
or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein n is 2, and the two Es dimerize with each other to form an Fc domain.
12. The method of claim 1 , wherein each E comprises an amino acid sequence independently selected from of any one of SEQ ID NOs: 1-138.
13. The method of claim 1 , wherein each E comprises an amino acid sequence independently selected from any one of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 76, and SEQ ID NO: 77.
14. The method of claim 1 , wherein the influenza virus is influenza virus A, influenza virus B, influenza virus C, or a parainfluenza virus.
15. A method of treating a subject having an influenza infection, the method comprising administering to the subject a conjugate described by the structure:
wherein J is an Fc domain comprising two Fc domain monomers;
T is an integer from 1 to 20,
L is a linker;
R 7 is selected from C 1 -C 20 alkyl; and
the squiggly line indicates that L is covalently attached to J;
or a pharmaceutically acceptable salt thereof.
16. The method of claim 15 , wherein R 7 is methyl, ethyl, propyl, or butyl.
17. The method of claim 16 , wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.
18. The method of claim 17 , wherein the conjugate has the structure of:
or a pharmaceutically acceptable salt thereof.
19. The method of claim 15 , wherein each Fc domain monomer comprises an amino acid sequence independently selected from any one of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 76, and SEQ ID NO: 77.
20. The method of claim 15 , wherein the influenza virus is influenza virus A, influenza virus B, influenza virus C, or a parainfluenza virus.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 31, 2022
From: BORCHARDT, ALLEN; BRADY, THOMAS P.; CHEN, ZHI-YONG; LAM, THANH; TARI, LESLIE W.
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 061594/0657 →
Continuity (14)
Division
17236745
· Apr 21, 2021
Continuation
PCTUS2020049772
· Sep 8, 2020
Provisional Application
63062377
· Aug 6, 2020
Provisional Application
63032488
· May 29, 2020
Provisional Application
62988304
· Mar 11, 2020
Provisional Application
62984705
· Mar 3, 2020
Provisional Application
62970491
· Feb 5, 2020
Provisional Application
62966500
· Jan 27, 2020
Provisional Application
62959857
· Jan 10, 2020
Provisional Application
62948143
· Dec 13, 2019
Provisional Application
62941405
· Nov 27, 2019
Provisional Application
62897036
· Sep 6, 2019
References Cited (107)
US 6495580B1
· Nitz et al.
· 2002
[cited by applicant]
US 6548476B1
· Wu et al.
· 2003
[cited by applicant]
US 6680054B1
· Reece et al.
· 2004
[cited by applicant]
US 7214707B2
· Demaine et al.
· 2007
[cited by applicant]
US 8486938B2
· Babaoglu et al.
· 2013
[cited by applicant]
US 9469676B2
· Camphausen et al.
· 2016
[cited by applicant]
US 9738652B2
· Hu et al.
· 2017
[cited by applicant]
US 20110243966A1
· Farrington et al.
· 2011
[cited by applicant]
US 20190233525A1
· Igawa et al.
· 2019
[cited by applicant]
US 20210220478A1
· Balkovec et al.
· 2021
[cited by applicant]
US 20210228727A1
· Balkovec et al.
· 2021
[cited by applicant]
US 20240285786A1
· Tari
· 2024
[cited by examiner]
EP 1196408B1
· 2004
[cited by applicant]
WO WO03040136A1
· 2003
[cited by applicant]
WO WO2007022494A2
· 2007
[cited by applicant]
WO WO2010093706A2
· 2010
[cited by applicant]
WO WO2014060411A1
· 2014
[cited by applicant]
WO WO2017046625A1
· 2017
[cited by applicant]
WO WO2018006063A1
· 2018
[cited by applicant]
WO WO2018128826A1
· 2018
[cited by applicant]
WO WO2020051498A1
· 2020
[cited by examiner]
WO WO2020252393A1
· 2020
[cited by applicant]
WO WO2020252396A1
· 2020
[cited by applicant]
WO WO2021046549A1
· 2021
[cited by applicant]
Macdonald, S., R. Cameron et al., “Dimeric Zanamivir Conjugates with Various Linking Groups Are Potent, Long-Lasting Inhibitors of Influenza Neuraminidase Including H5N1 Avian Influenza”, J Med Chem. (2005), 48(8), pp. …
[cited by examiner]
U.S. Appl. No. 18/464,421, Balkovec et al.
[cited by applicant]
Battles et al., “Molecular mechanism of respiratory syncytial virus fusion inhibitors,” available in PMC Feb. 1, 2016, published in final edited form as: Nat Chem Biol 12(2):87-93 (2016) (23 pages).
[cited by applicant]
Zhong et al., “Amide-sialoside protein conjugates as neomucin bioshields prevent influenza virus infection,” Carbohydr Res. 495:108088 (Jun. 2020) (7 pages).
[cited by applicant]
Levin et al., “Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria),” Open Forum Infectious Diseases 6(Suppl. 2):S313 (O…
[cited by applicant]
Walker et al., “Spin-labeling of Dexamethasone: Radical Stability vs. Temporal Resolution of EPR-Spectroscopy on Biological Samples,” Z Phys Chem. 232(5-6):883-891 (Apr. 2018) (9 pages).
[cited by applicant]
Yu et al., “Guanidinothiosialoside-Human Serum Albumin Conjugate Mimics mucin Barrier to Restrict Influenza Infection,” Int J Biol Macromol. 162:84-91 (Jun. 2020) (8 pages).
[cited by applicant]
Döhrmann et al., “Fc-Mediated Effector Function Contributes to Potency of Novel Antiviral Fc-Conjugate CB-012,” Options X for the Control of Influenza, Abstract No. 11094, 507 (Aug. 2019) (1 page).
[cited by applicant]
Ali et al., “A Phase 2a Study to Evaluate the Safety of MEDI8852 in Outpatient Adults with Acute, Uncomplicated Influenza A,” Open Forum Infectious Diseases. 4:S519, Abstract 1656 (2017) (1 page).
[cited by applicant]
Almaguer et al., “CD377, a Novel Antiviral Fc-Conjugate, Demonstrates a Lower Resistance Potential than Baloxavir and Oseltamivir against Pandemic Influenza A (H1N1),” Abstract Book—30th ECCMID Apr. 18-21, 2020. p. 2766…
[cited by applicant]
Borchardt et al., “CB-012—A Novel Antiviral-Fc Conjugate for Treatment and Prevention of Influenza Virus,” ASM Microbe, Jun. 20-24, San Francisco, California. Poster HMB-385 (2019) (1 page).
[cited by applicant]
Borrok et al., “pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling,” J Biol Chem. 290(7):4282-4290 (2015) (10 pages).
[cited by applicant]
Cheng et al., “From Neuraminidase Inhibitors to Conjugates: a Step Towards Better Anti-Influenza Drugs?” Future Med Chem. 6(7): 757-774 (2014).
[cited by applicant]
Devanaboyina et al., “Engineered clearing agents for the selective depletion of antigen-specific antibodies,” Nat Commun. 8:15314 (2017) (6 pages).
[cited by applicant]
Döhrmann et al., “CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Potent Broad-Spectrum Activity in Multiple in vitro Assays Against Influenza A and B,” Abstract Book—30th ECCMID Apr. 18-21, 2020. p. 4170. Abstract …
[cited by applicant]
Döhrmann et al., “CD377, A Novel Antiviral Fc-Conjugate, Demonstrates Superior Reduction of Viral Burden and Cytokine Levels Compared to Oseltamivir in a Lethal Mouse Model of Influenza A (H1N1) Infection,” Abstract Boo…
[cited by applicant]
Döhrmann et al., “Fc-Mediated Effector Function Contributes to Potency of Novel Cloudbreak Antiviral Fc-Conjugate (AVC) CB-012,” Options X, Aug. 28-Sep. 1, Singapore (2019) (1 page).
[cited by applicant]
Döhrmann et al., “Fc-Mediated Fcgamma Receptor Engagement of CD377, a Novel Antiviral Fc-Conjugate, Translates Into Potent Antibody-Dependent Cellular Phagocytosis and Antibody-Dependent Cellular Cytotoxicity Activity,”…
[cited by applicant]
Döhrmann, “CD377, A Novel Antiviral Fc-Conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza A (H1N1) in Mouse and Ferret Models,” IDWeek, Oct. 21-25, Virtual Event. Abstract 162 (2020) (30 pages).
[cited by applicant]
Extended European Search Report for European Application No. 19857366.9, dated Jul. 5, 2022 (12 pages).
[cited by applicant]
Fu et al., “Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses,” J Med Chem. 59(13): 6303-6312 (2016).
[cited by applicant]
Greengard et al., “The Anti-Influenza Virus Agent 4-GU-DANA (Zanamivir) Inhibits Cell Fusion Mediated by Human Parainfluenza Virus and Influenza Virus Ha,” J Virol. 74(23):11108-11114 (2000) (7 pages).
[cited by applicant]
Gubareva et al., “Antivirals Targeting the Neuraminidase,” Cold Spring Harb Perspect Med. 12(1):a038455 (2022) (21 pages).
[cited by applicant]
Guillon et al., “Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin-neuraminidase inhibitors,” Nat Commun. 5:5268 (2014) (11 pages).
[cited by applicant]
Hadházi et al., “A Sulfonozanamivir Analogue Has Potent Anti-influenza Virus Activity,” ChemMedChem. 13:785-789 (2018).
[cited by applicant]
Hanessian et al., “Total Synthesis of A-315675: A Potent Inhibitor of Influenza Neuraminidase,” J Am Chem Soc. 124(17):4716-4721 (2002).
[cited by applicant]
Hayakawa et al., “Chemically Programmed Antibody is a Long-lasting and Potent Inhibitor of Influenza Neuraminidase,” available in PMC Oct. 15, 2013, published in final edited form as: Chembiochem. 13(15):2191-2195 (2012…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/050018, mailed Feb. 19, 2020 (11 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/047490, mailed Mar. 18, 2021 (18 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/049772, mailed Feb. 4, 2021 (13 pages).
[cited by applicant]
Search Report and Written Opinion for Singaporean Patent Application No. 11202103313R, dated Nov. 8, 2022 (8 pages).
[cited by applicant]
Kallewaard et al., “Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes,” Cell. 166(3):596-608 (2016) (34 Pages).
[cited by applicant]
Kati et al., “In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication,” Antimicrob Agents Chemother. 46(4):1014-1021 (2002).
[cited by applicant]
Laborda et al., “Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity,” Molecules. 21(11):1513 (2016) (40 pages).
[cited by applicant]
Levin et al., “Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, against Influenza A (H1N1) In a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID),” Options X, Aug. 28-Sep. 1, Singapore (2019) (1 page).
[cited by applicant]
Levin et al., “Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, in Lethal Mouse Models of Oseltamivir-Sensitive and -Resistant Influenza A H1N1 and H3N2 Isolates,” Options X, Aug. 28-Sep. 1, Singapore (2019) (1 page).
[cited by applicant]
Levin et al., “Efficacy of CD377, A Novel Antiviral Fc-Conjugate Against Seasonal Influenza in Lethal Mouse Models,” Abstract Book—30th ECCMID Apr. 18-21, 2020. p. 2804. Abstract 5793 (2020) (1 page).
[cited by applicant]
Levin et al., “Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Influenza A (H1N1) in a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID),” Abstract Book—30th ECCMID Apr. 18-21, 2020. p. 2871. Abst…
[cited by applicant]
Levin et al., “Efficacy of CD377, a Novel Antiviral Fc-Conjugate, by Multiple Dosing Routes Against Influenza A (H1N1), and Activity against Oseltamivir-Resistant Isolates in Lethal Mouse Models,” ESWI Conference, Virtu…
[cited by applicant]
Levin et al., “Evaluation of CD377, A Novel Antiviral Fc-Conjugate (AVC) In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models,” IDWeek, Oct. 21-25, Virtual Event. Poster 1…
[cited by applicant]
Levin et al., “In Vitro Potency and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Highly Pathogenic Avian Influenza (HPAI),” Cidara Therapeutics Inc., ESWI 2020, Virtual Event (Dec. 2020) (1 page).
[cited by applicant]
Levin et al., “Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria),” IDWeek, Oct. 2-6, Washington, D.C. Poster 689 (201…
[cited by applicant]
Levin, “Efficacy of CD377, A Novel Antiviral Fc-Conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models,” IDWeek, Oct. 21-25, Virtual Event. Abstract 159 (2020) (17 pages).
[cited by applicant]
Lin et al., “Synthesis of Acylguanidine Zanamivir Derivatives as Neuraminidase Inhibitors are the Evaluation of their Bio-Activities,” Org Biomol Chem. 11(24): 3943-8 (2013).
[cited by applicant]
Locke et al., “Novel Antiviral Fc-Conjugate CB-012 Demonstrates Potent Activity in Cytopathic Effect (CPE) and Viral Growth Inhibition Assays against Influenza A and B Strains,” Options X, Aug. 28-Sep. 1, Singapore (201…
[cited by applicant]
Locke, “Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains,” ESWI Conference, Virtual Event.…
[cited by applicant]
Macdonald et al., “Dimeric Zanamivir Conjugates with Various Linking Groups are Potent, Long-Lasting Inhibitors of Influenza Neuraminidase Including H5N1 Avian Influenza,” J Med Chem. 48(8): 2964-2971 (Mar. 2005).
[cited by applicant]
Macdonald et al., “Potent and Long-Acting Dimeric Inhibitors of Influenza Virus Neuraminidase are Effective at a Once-Weekly Dosing Regimen,” Antimicrob Agents Chemother. 48(12): 4542-9 (Dec. 2004).
[cited by applicant]
Mallory et al., “A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers,” Biologicals. 50:81-86 (2017) (6 pages).
[cited by applicant]
McKimm-Breschkin et al., “Structural and Functional Analysis of Anti-Influenza Activity of 4-,7-, 8- and 9-Deoxygenated 2,3-Difluoro-N-acetylneuraminic Acid Derivatives,” J Med Chem. 61(5): 1921-1933 (2018) (13 pages).
[cited by applicant]
McKimm-Breschkin et al., “Tethered neuraminidase inhibitors that bind an influenza virus: a first step towards a diagnostic method for influenza,” Angew Chem Int Ed Engl. 42(27):3118-21 (2003) (5 pages).
[cited by applicant]
Meng et al., “Multivalent neuraminidase hydrolysis resistant triazole-sialoside protein conjugates as influenza-adsorbents,” Chinese Chemical Letters. 29:76-80 (2018) (5 pages).
[cited by applicant]
Moscona, “Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease,” J Clin Invest. 115(7):1688-1698 (2005) (11 pages).
[cited by applicant]
Ong et al., “Next Generation Antiviral Conjugate (AVC): Stable, Safe, and Single,” IDWeek, Oct. 21-25, Virtual Event. Poster 1283 (2020) (1 page).
[cited by applicant]
Ong et al., “Preclinical efficacy, pharmacokinetics and safety of CD377, a novel antiviral Fc-conjugate against influenza,” Abstract Book—30th ECCMID Apr. 18-21, 2020. p. 2489. Abstract 5126 (2020) (1 page).
[cited by applicant]
Ong et al., “Preclinical Efficacy, Pharmacokinetics, and Safety of CB-012, A Novel Antiviral Fc- Conjugate against Influenza,” Options X, Aug. 28-Sep. 1, Singapore (2019) (1 page).
[cited by applicant]
Paules et al., “The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses,” J Infect Dis. 216(3):356-65 (2017) (10 pages).
[cited by applicant]
Rota et al., “Potent Inhibitors against Newcastle Disease Virus Hemagglutinin-Neuraminidase,” ChemMedChem. 13:236-240 (2018) (5 pages).
[cited by applicant]
Shtyrya et al., “Influenza Virus Neuraminidase: Structure and Function,” Acta Naturae. 1(2):26-32 (2009).
[cited by applicant]
Tarbet et al., “A Zanamivir Dimer with Prophylactic and Enhanced Therapeutic Activity against Influenza viruses,” J Antimicrob Chemother. 69(8): 2164-74 (2014).
[cited by applicant]
Tari, “Cloudbreak Influenza,” EECMID 2019, Apr. 13-16, Amsterdam, Netherlands (2019) (22 pages).
[cited by applicant]
Tari, Transcript of Cidara Therapeutics YouTube video: “Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak® Influenza Antiviral Conjugates (AVCs),” <https://www.youtube.com/watch?v…
[cited by applicant]
Wang et al., “Peramivir conjugates as orally available agents against influenza H275Y mutant,” Eur J Med Chem. 145:224-34 (2018) (3 pages) (Abstract Only).
[cited by applicant]
Watson et al., “Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase,” Bioorg Med Chem Lett. 14(6):1589-92 (2004).
[cited by applicant]
Weight et al., “Zanamivir conjugated to poly-L-glutamine is much more active against influenza viruses in mice and ferrets than the drug itself,” available in PMC Mar. 25, 2014, published in final edited form as: Pharm …
[cited by applicant]
Wen et al., “Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus,” J Med Chem. 52(15):4903-10 (2009).
[cited by applicant]
Wold et al., “Fc-Small Molecule Antibody Mimetics,” Bioconjug Chem. 26(12):2311-4 (2015) (23 pages).
[cited by applicant]
Zhao et al., “Multivalent zanamivir-bovine serum albumin conjugate as a potent influenza neuraminidase inhibitor,” Journal of Carbohydrate Chemistry. 36(4-6):235-246 (2017) (13 pages).
[cited by applicant]